Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Orient Gene Biotech Co's quarterly market cap
declined
from Sep. 2025 (¥5,211 Mil) to Dec. 2025 (¥4,723 Mil) and
declined
from Dec. 2025 (¥4,723 Mil) to Mar. 2026 (¥4,596 Mil).
Zhejiang Orient Gene Biotech Co's annual market cap
declined
from Dec. 2023 (¥7,209 Mil) to Dec. 2024 (¥5,913 Mil) and
declined
from Dec. 2024 (¥5,913 Mil) to Dec. 2025 (¥4,723 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zhejiang Orient Gene Biotech Co's Enterprise Value for Today is ¥1,619 Mil.
Zhejiang Orient Gene Biotech Co (SHSE:688298) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zhejiang Orient Gene Biotech Co Market Cap Related Terms
Zhejiang Orient Gene Biotech Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688298 vs ABT, SYK, MDT: Market Cap Comparison
For the Medical Devices subindustry, Zhejiang Orient Gene Biotech Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Orient Gene Biotech Co Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zhejiang Orient Gene Biotech Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Zhejiang Orient Gene Biotech Co's Market Cap falls into.
Zhejiang Orient Gene Biotech Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Orient Gene Biotech Co (SHSE:688298) has a Market Cap of ¥3,603 Mil as of Jul. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. According to the industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #248 out of 863 companies in the Medical Devices & Instruments industry, placing it in the top 28.7%.
Is Zhejiang Orient Gene Biotech Co's Market Cap too high?
Zhejiang Orient Gene Biotech Co's current Market Cap is ¥3,603 Mil. Based on the distribution chart, Zhejiang Orient Gene Biotech Co ranks #248 out of 863 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zhejiang Orient Gene Biotech Co has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Orient Gene Biotech Co's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #248 out of 863 companies for Market Cap. This puts Zhejiang Orient Gene Biotech Co in the upper half of its industry. The industry median Market Cap is 114.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 114.85, based on 863 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 114.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Orient Gene Biotech Co's current Market Cap is ¥3,603 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Orient Gene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co (SHSE:688298) is currently considered Possible Value Trap. The stock's GF Value™ is ¥30.81, compared to a current price of ¥17.87 — trading 42% below its estimated fair value. The current Market Cap is ¥3,603 Mil. Zhejiang Orient Gene Biotech Co's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Zhejiang Orient Gene Biotech Co (SHSE:688298), the current Market Cap is ¥3,603 Mil as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Orient Gene Biotech Co (SHSE:688298) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co stock appears to be undervalued.
The current stock price of ¥17.87 is trading 42% below its estimated GF Value™ of ¥30.81.
GuruFocus considers Zhejiang Orient Gene Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688298:
Market Cap: ¥3,603 Mil
GF Value™: ¥30.81 vs. price of ¥17.87 (42% below fair value)
No single metric tells the full story. See the SHSE:688298 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Orient Gene Biotech Co Business Description
Zhejiang Orient Gene Biotech Co Ltd is engaged in production, research, development and sale of vitro diagnostic products. The company's products include Genetic diagnosis, Colloidal gold rapid diagnostic tests, Dry chemical strips (urinalysis), Bio-liquid diagnostic kits, Clinical test instruments, POCT time-resolved Fluor immunoassay Test kit (TRFI), and Raw materials.
51GF Score
Get the complete analysis for SHSE:688298
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688298 has been successfully added to your 
